We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

110 hedge funds and large institutions have $534M invested in 4D Molecular Therapeutics in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

27% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 33

10% more funds holding

Funds holding: 100 → 110 (+10)

1.21% more ownership

Funds ownership: 98.47% → 99.68% (+1.2%)

3% more call options, than puts

Call options by funds: $294K | Put options by funds: $286K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

28% less capital invested

Capital invested by funds: $745M → $534M (-$212M)

Holders
110
Holders Change
+10
Holders Change %
+10%
% of All Funds
1.75%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
42
Reduced
33
Closed
10
Calls
$294K
Puts
$286K
Net Calls
+$8K
Net Calls Change
+$603K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$18.3M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.01M
3
BlackRock
BlackRock
New York
+$3.5M
4
NHAS
Novo Holdings A/S
Denmark
+$3.35M
5
GC
GMT Capital
Georgia
+$2.53M

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$11M
2
GPP
Great Point Partners
Connecticut
-$6.32M
3
State Street
State Street
Massachusetts
-$5.57M
4
Invesco
Invesco
Georgia
-$3.31M
5
Morgan Stanley
Morgan Stanley
New York
-$1.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$2.52M +$418K +25,000 +14%
Wellington Management Group
27
Wellington Management Group
Massachusetts
$2.2M +$60.8K +3,638 +2%
Verition Fund Management
28
Verition Fund Management
Connecticut
$2.13M +$1.58M +94,428 +130%
Rafferty Asset Management
29
Rafferty Asset Management
New York
$2.05M -$600K -35,869 -18%
First Manhattan
30
First Manhattan
New York
$2.04M +$266K +15,900 +11%
Goldman Sachs
31
Goldman Sachs
New York
$2.01M -$602K -35,991 -19%
GC
32
GMT Capital
Georgia
$1.92M +$2.53M +151,200 New
Citadel Advisors
33
Citadel Advisors
Florida
$1.82M +$2.08M +124,335 +658%
Bank of America
34
Bank of America
North Carolina
$1.75M +$586K +35,022 +34%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.73M +$325K +19,434 +17%
SCM
36
Soleus Capital Management
Connecticut
$1.58M -$1.6M -95,400 -44%
N
37
Nuveen
North Carolina
$1.37M +$168K +10,047 +10%
Two Sigma Investments
38
Two Sigma Investments
New York
$1.3M -$1.39M -83,276 -45%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$1.11M -$421K -25,146 -22%
AllianceBernstein
40
AllianceBernstein
Tennessee
$1.06M -$89.8K -5,370 -6%
PAM
41
Panagora Asset Management
Massachusetts
$964K +$1.27M +75,688 New
Barclays
42
Barclays
United Kingdom
$941K -$1.15M -68,529 -48%
Voloridge Investment Management
43
Voloridge Investment Management
Florida
$926K -$1.05M -62,894 -46%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$744K +$158K +9,461 +19%
Citigroup
45
Citigroup
New York
$696K -$57.8K -3,458 -6%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$664K +$286K +17,116 +49%
Squarepoint
47
Squarepoint
New York
$608K +$553K +33,056 +225%
Jane Street
48
Jane Street
New York
$597K +$86K +5,141 +12%
Swiss National Bank
49
Swiss National Bank
Switzerland
$587K -$259K -15,500 -25%
UBS Group
50
UBS Group
Switzerland
$572K -$150K -8,953 -17%
1
2
3 4 5

FDMT Hedge Fund Activity: Q3 2023 in Review

110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2023, worth a combined $534M — down 28% from $745M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new FDMT positions and 10 closed out — a net gain of 10 holders — while 42 added to existing stakes and 33 trimmed.

The largest buyer was RA Capital Management, adding an estimated $18.3M. The largest seller was Deutsche Bank, cutting an estimated $11M.

  • 110 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2023, up from 100 in Q2 2023.
  • Funds reported $534M of 4D Molecular Therapeutics stock for Q3 2023, down 28% quarter-over-quarter.
  • 20 funds opened new 4D Molecular Therapeutics positions in Q3 2023 and 10 closed out, a net change of +10 holders.
  • The largest 4D Molecular Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $18.3M added.
  • The largest 4D Molecular Therapeutics seller in Q3 2023 was Deutsche Bank, an estimated $11M sold.

Based on aggregated 13F filings for Q3 2023.